Display options
Cite
Chitadze G, Flüh C, Quabius ES, et al. In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment. Oncoimmunology. 2017;6(11):e1358839doi: 10.1080/2162402X.2017.1358839.
Chitadze, G., Flüh, C., Quabius, E. S., Freitag-Wolf, S., Peters, C., Lettau, M., Bhat, J., Wesch, D., Oberg, H. H., Luecke, S., Janssen, O., Synowitz, M., Held-Feindt, J., & Kabelitz, D. (2017). In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment. Oncoimmunology, 6(11), e1358839. https://doi.org/10.1080/2162402X.2017.1358839
Chitadze, Guranda, et al. "In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment." Oncoimmunology vol. 6,11 (2017): e1358839. doi: https://doi.org/10.1080/2162402X.2017.1358839
Chitadze G, Flüh C, Quabius ES, Freitag-Wolf S, Peters C, Lettau M, Bhat J, Wesch D, Oberg HH, Luecke S, Janssen O, Synowitz M, Held-Feindt J, Kabelitz D. In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment. Oncoimmunology. 2017 Aug 08;6(11):e1358839. doi: 10.1080/2162402X.2017.1358839. eCollection 2017. PMID: 29147621; PMCID: PMC5674968.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2017 Aug 08;6(11):e1358839. doi: 10.1080/2162402X.2017.1358839. eCollection 2017.

In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment.

Oncoimmunology

Guranda Chitadze, Charlotte Flüh, Elgar Susanne Quabius, Sandra Freitag-Wolf, Christian Peters, Marcus Lettau, Jaydeep Bhat, Daniela Wesch, Hans-Heinrich Oberg, Stefanie Luecke, Ottmar Janssen, Michael Synowitz, Janka Held-Feindt, Dieter Kabelitz

Affiliations

  1. Institute of Immunology, University Hospital Schleswig-Holstein (UKSH) Campus Kiel, Kiel, Schleswig-Hostein, Germany.
  2. Dept. of Neurosurgery, UKSH Campus Kiel, Kiel, Schleswig-Hostein, Germany.
  3. Dept. of Oto-Rhino-Laryngology, UKSH Campus Kiel, Kiel, Schleswig-Hostein, Germany.
  4. Institute of Medical Informatics and Statistics, Kiel University, Kiel, Schleswig-Hostein, Germany.

PMID: 29147621 PMCID: PMC5674968 DOI: 10.1080/2162402X.2017.1358839

Abstract

Despite aggressive treatment regimens based on surgery and radiochemotherapy, the prognosis of patients with grade IV glioblastoma multiforme (GBM) remains extremely poor, calling for alternative options such as immunotherapy. Immunological mechanisms including the Natural Killer Group 2 member D (NKG2D) receptor-ligand system play an important role in tumor immune surveillance and targeting the NKG2D system might be beneficial. However, before considering any kind of immunotherapy, a precise characterization of the immune system is important, particularly in GBM patients where conventional therapies with impact on the immune system are frequently co-administered. Here we performed an in-depth immunophenotyping of GBM patients and age-matched healthy controls and analyzed NKG2D ligand expression on primary GBM cells

Keywords: Dexamethasone; NKG2D; gamma/delta T cells; glioblastoma multiforme

References

  1. J Biol Regul Homeost Agents. 2016 Jan-Mar;30(1):17-30 - PubMed
  2. J Neurooncol. 2007 Dec;85(3):271-80 - PubMed
  3. Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):E3529-37 - PubMed
  4. Oncology (Williston Park). 2016 Aug;30(8):713-21 - PubMed
  5. Circulation. 1998 Nov 24;98(21):2307-13 - PubMed
  6. Cancer Res. 2004 Dec 15;64(24):9172-9 - PubMed
  7. J Leukoc Biol. 2017 Jun;101(6):1317-1323 - PubMed
  8. J Neurooncol. 2014 Jan;116(1):31-9 - PubMed
  9. Blood. 2001 May 15;97(10):3146-51 - PubMed
  10. Trends Immunol. 2017 Feb;38(2):104-115 - PubMed
  11. J Neurochem. 2009 Dec;111(6):1447-56 - PubMed
  12. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12823-8 - PubMed
  13. J Neuroimmunol. 2013 Nov 15;264(1-2):71-83 - PubMed
  14. J Exp Med. 2013 Nov 18;210(12):2675-92 - PubMed
  15. Brain. 2006 Sep;129(Pt 9):2416-25 - PubMed
  16. Nat Protoc. 2006;1(3):1559-82 - PubMed
  17. Leukemia. 2013 Jun;27(6):1328-38 - PubMed
  18. Cancer Immunol Immunother. 2006 Sep;55(9):1072-80 - PubMed
  19. J Clin Oncol. 2004 Feb 15;22(4):610-6 - PubMed
  20. Alzheimers Dement (Amst). 2016 Aug 19;4:99-106 - PubMed
  21. J Immunol. 2014 Sep 15;193(6):2764-2771 - PubMed
  22. J Neurooncol. 2016 Mar;127(1):1-13 - PubMed
  23. N Engl J Med. 2008 Jul 31;359(5):492-507 - PubMed
  24. Chin J Cancer. 2015 Apr 09;34(4):161-5 - PubMed
  25. J Neurooncol. 2011 Jan;101(2):179-88 - PubMed
  26. Clin Exp Immunol. 2015 Apr;180(1):1-10 - PubMed
  27. Front Immunol. 2015 Mar 04;6:97 - PubMed
  28. Trends Immunol. 2017 Sep;38(9):668-678 - PubMed
  29. Neuro Oncol. 2009 Aug;11(4):357-67 - PubMed
  30. Oncol Lett. 2016 Oct;12 (4):2924-2929 - PubMed
  31. Neurology. 1994 Apr;44(4):675-80 - PubMed
  32. Cancer Cell. 2014 Oct 13;26(4):565-76 - PubMed
  33. Br J Cancer. 2015 Jul 14;113(2):232-41 - PubMed
  34. Mol Ther. 2014 Aug;22(8):1416-1422 - PubMed
  35. Biomed Res Int. 2016;2016:7487313 - PubMed
  36. N Engl J Med. 2011 Aug 25;365(8):725-33 - PubMed
  37. Front Surg. 2016 Mar 02;3:11 - PubMed
  38. BMC Cancer. 2015 Sep 04;15:617 - PubMed
  39. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  40. Oncoimmunology. 2016 Mar 30;5(6):e1168554 - PubMed
  41. J Pediatr. 1998 Jan;132(1):53-6 - PubMed
  42. J Neurooncol. 2017 Jan;131(1):1-9 - PubMed
  43. Surg Neurol Int. 2014 Jun 07;5:89 - PubMed
  44. J Clin Invest. 1999 May 15;103(10):1437-49 - PubMed
  45. Elife. 2016 Jan 21;5:e10820 - PubMed
  46. PLoS One. 2012;7(6):e39956 - PubMed
  47. Cell Mol Life Sci. 2014 Jun;71(12):2335-46 - PubMed
  48. Immunotargets Ther. 2014 Mar 13;3:55-66 - PubMed
  49. Clin Cancer Res. 2016 Dec 1;22(23 ):5795-5804 - PubMed
  50. Pancreatology. 2016 Nov - Dec;16(6):1069-1079 - PubMed
  51. JCI Insight. 2016 Apr 21;1(5):null - PubMed
  52. Blood. 2010 Sep 23;116(12):2164-72 - PubMed
  53. Neuro Oncol. 2011 Apr;13(4):393-400 - PubMed
  54. Clin Exp Immunol. 1976 Apr;24(1):54-62 - PubMed
  55. Clin Dev Immunol. 2012;2012:831090 - PubMed
  56. J Exp Med. 2003 Jan 20;197(2):163-8 - PubMed
  57. Expert Rev Clin Pharmacol. 2011 Mar;4(2):233-42 - PubMed
  58. Br J Haematol. 2009 Jan;144(2):245-50 - PubMed
  59. J Cell Physiol. 2012 Feb;227(2):558-68 - PubMed
  60. Anticancer Res. 2007 Jul-Aug;27(4A):2041-5 - PubMed
  61. Trends Immunol. 2001 Nov;22(11):633-40 - PubMed
  62. PLoS One. 2013 Aug 07;8(8):e68729 - PubMed
  63. Oncoimmunology. 2015 Dec 10;5(4):e1093276 - PubMed
  64. Scand J Immunol. 2013 Aug;78(2):120-9 - PubMed
  65. N Engl J Med. 2015 Sep 24;373(13):1270-1 - PubMed
  66. Cancer Immunol Immunother. 2015 May;64(5):551-62 - PubMed
  67. Blood. 2007 Mar 1;109(5):2078-85 - PubMed
  68. Oncoimmunology. 2015 Oct 29;5(5):e1108513 - PubMed
  69. J Immunol. 1995 May 1;154(9):4719-25 - PubMed
  70. PLoS One. 2013;8(1):e51805 - PubMed
  71. N Engl J Med. 2005 Mar 10;352(10 ):987-96 - PubMed
  72. Int J Cancer. 2013 Oct 1;133(7):1557-66 - PubMed

Publication Types